Whales with a lot of money to spend have taken a noticeably bullish stance on Gilead Sciences.
Looking at options history for Gilead Sciences (NASDAQ:GILD) we detected 9 trades.
If we consider the specifics of each trade, it is accurate to state that 44% of the investors opened trades with bullish expectations and 44% with bearish.
From the overall spotted trades, 3 are puts, for a total amount of $108,977 and 6, calls, for a total amount of $345,373.
What's The Price Target?
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $55.0 and $75.0 for Gilead Sciences, spanning the last three months.
Analyzing Volume & Open Interest
In today's trading context, the average open interest for options of Gilead Sciences stands at 2975.88, with a total volume reaching 106.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Gilead Sciences, situated within the strike price corridor from $55.0 to $75.0, throughout the last 30 days.
Gilead Sciences 30-Day Option Volume & Interest Snapshot
Biggest Options Spotted:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| GILD | CALL | TRADE | BULLISH | 01/17/25 | $18.2 | $18.2 | $18.2 | $55.00 | $91.0K | 215 | 1 |
| GILD | CALL | TRADE | BEARISH | 06/20/25 | $10.1 | $10.05 | $10.05 | $67.50 | $66.3K | 751 | 0 |
| GILD | PUT | SWEEP | BEARISH | 07/26/24 | $1.04 | $1.0 | $1.0 | $73.00 | $55.9K | 72 | 7 |
| GILD | CALL | SWEEP | BULLISH | 06/20/25 | $10.1 | $9.9 | $10.0 | $67.50 | $54.4K | 751 | 0 |
| GILD | CALL | TRADE | BULLISH | 09/20/24 | $6.4 | $6.3 | $6.38 | $67.50 | $53.5K | 871 | 1 |
About Gilead Sciences
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
In light of the recent options history for Gilead Sciences, it's now appropriate to focus on the company itself. We aim to explore its current performance.
Present Market Standing of Gilead Sciences
- Currently trading with a volume of 2,761,226, the GILD's price is down by 0.0%, now at $73.51.
- RSI readings suggest the stock is currently may be approaching overbought.
- Anticipated earnings release is in 20 days.
What Analysts Are Saying About Gilead Sciences
3 market experts have recently issued ratings for this stock, with a consensus target price of $82.33333333333333.
- An analyst from Raymond James upgraded its action to Outperform with a price target of $93.
- Maintaining their stance, an analyst from Baird continues to hold a Neutral rating for Gilead Sciences, targeting a price of $80.
- An analyst from RBC Capital has revised its rating downward to Sector Perform, adjusting the price target to $74.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Gilead Sciences options trades with real-time alerts from Benzinga Pro.